What is the 13F Pro Quality Score for IRWD?

13F Pro ranks IRONWOOD PHARMACEUTICALS INC (IRWD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IRWD's current score at https://13fpro.ai/company/IRWD (free sign-up required for the full ranking).

Which hedge funds own the most IRWD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IRWD include BlackRock,, ARMISTICE CAPITAL,, Sarissa Capital Management. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/IRWD as soon as new 13F filings post.

Where does 13F Pro source IRWD data?

All IRONWOOD PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. IRONWOOD PHARMACEUTICALS INC files with the SEC under CIK 1446847. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IRWD in?

IRONWOOD PHARMACEUTICALS INC (IRWD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are IRWD's largest expenses?

IRONWOOD PHARMACEUTICALS INC's latest 10-Q reports these as the largest expense items: Research and development ($22.4M, -4% YoY); Selling, general and administrative ($11.3M, -33% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is IRWD research updated on 13F Pro?

IRWD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IRONWOOD PHARMACEUTICALS INC(IRWD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1446847 IRWD stock profile & AI dashboard →

13F Pro Quality Score

60.8/100

Rank #834 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

20.6/100

Profitability

94.4/100

Balance Sheet

99.2/100

Earnings Quality

72.7/100

Free Cash Flow

94.1/100

Institutional Flow

4.1/100

Revenue Scale

33.0/100

Dilution Risk

22.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IRWD Scores 61/100

exact factor attribution · 2026-09-11

IRWD's composite is driven by profitability and free cash flow, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+6.7 pts

94th pct

Free cash flow

+6.6 pts

94th pct

Capital efficiency

+4.9 pts

99th pct

Earnings growth

+2.5 pts

99th pct

Earnings quality

+2.3 pts

73th pct

Shareholder dilution

-1.4 pts

23th pct

Institutional flow

-2.3 pts

4th pct

Scale

-2.5 pts

33th pct

Revenue growth

-5.9 pts

21th pct

Latest change (2026-08-07): 56 → 36 · ↓ Profit margin 87→27; ↓ Capital efficiency 95→25; despite ↑ Revenue growth 17→29

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in IRWD

Events flagged as statistical outliers against IRWD's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-07
IRWD quality score dropped 20 points (56→36) on a new filing
View source filing →

IRWD Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for IRONWOOD PHARMACEUTICALS INC (IRWD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRWD at 60.8/100 on a 32-signal composite quality model, placing it at rank #834 of 2,962 stocks — the top half of the AI-ranked universe. IRWD scores in the top quartile across balance sheet strength (99.2), profitability (94.4), free cash flow (94.1). Areas of concern include institutional flow (4.1) and revenue growth (20.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IRONWOOD PHARMACEUTICALS INC reports quarterly revenue of $113.0M, net income of $51.3M, an operating margin of 70.2%. Top institutional holders of IRWD by reported 13-F value include BlackRock, ARMISTICE CAPITAL, Sarissa Capital Management, based on the most recent SEC filings. IRWD trades on the Nasdaq exchange and files with the SEC under CIK 1446847. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRWD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IRONWOOD PHARMACEUTICALS INC directly from SEC EDGAR. IRONWOOD PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 31 and 71 since 2021, currently 60.8 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about IRONWOOD PHARMACEUTICALS INC

Quirks, history, and lore behind IRWD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · focused on gastrointestinal and other disorders · headquartered in Massachusetts.
2
The Numbers
A small-cap biopharma with annual revenues in the low hundreds of millions — most of it riding on a single blockbuster GI drug.
3
The History
Founded around 1998, the company spent years in development before scoring a major FDA approval for a drug targeting irritable bowel syndrome with constipation and chronic idiopathic constipation.
4
The Secret
Its lead drug works by staying almost entirely in the gut — it's minimally absorbed into the bloodstream, which is a feature, not a bug, making it unusually well-tolerated.
5
The Lore
The company co-promoted its flagship product with AbbVie for years before eventually going solo — a divorce that tested whether it could stand on its own in a very unglamorous corner of medicine.
6
The Giveaway
Its drug Linzess (linaclotide) is one of the best-selling treatments for constipation-predominant IBS — and yes, the ticker rhymes with a certain dense, heavy metal.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving IRWD's Business? Latest 10-Q Breakdown

AI-extracted from IRONWOOD PHARMACEUTICALS INC's 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue grew 33% YoY to $113.0M on higher LINZESS net profit share from AbbVie, driving net income up to $51.3M from $23.6M as expenses fell 15%.

Biggest Revenue Drivers

AbbVie (North America)$110.9M+28% YoY

Increase in share of net profits from LINZESS U.S. sales, driven primarily by increased net price and increased prescription demand

AbbVie (Europe and other)$1.1M+23% YoY

Biggest Revenue Drivers

Total revenue: $113.0M+33% YoY

AbbVie (North America)$110.9M+28% YoY

Increase in share of net profits from LINZESS U.S. sales, driven primarily by increased net price and increased prescription demand

AbbVie (Europe and other)$1.1M+23% YoY

Asahi Kasei Therapeutics (Japan, apraglutide)$0.5Mswung from -$2.7M to +$0.5M

Prior-year period included a $2.9M cumulative revenue reduction from increased estimated development costs

Astellas (Japan)$0.4M-7% YoY

Grand Life Sciences (China)$0.08M+7% YoY

Largest Expense Items

Research and development$22.4M-4% YoY

Decrease driven by lower external costs for the discontinued IW-3300 program and linaclotide, partially offset by higher apraglutide costs

Selling, general and administrative$11.3M-33% YoY

Decrease due to lower compensation/employee-related expenses and lower professional services expenses

Margins: Income from operations rose to $79.3M from $45.3M as revenue growth (+33% YoY) outpaced a 15% decline in total costs and expenses, driven by lower R&D and SG&A spend.

Watch Items from the Filing

In July 2026, Ironwood and AbbVie sued Alkem Laboratories over an ANDA challenge to LINZESS patents; the filing triggers an automatic FDA approval stay until December 12, 2028.
Cash and cash equivalents fell to $79.1M from $215.5M after repaying the $200.0M principal on the 2026 Convertible Notes at maturity in June 2026.
In May 2026, AstraZeneca assigned its China (including Hong Kong and Macau) linaclotide collaboration rights to Grand Life Sciences, a small but newly transitioned revenue territory.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$113.0M

Net Income

Q2 2026

$51.3M

Operating Margin

Q2 2026

70.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-15.7% YoY

$296.2MFY 2025

FY22 $410.6MFY23 $442.7MFY24 $351.4MFY25 $296.2M

Net Income

+2629.2% YoY

$24.0MFY 2025

FY22 $175.1MFY23 $-1.00BFY24 $880.0KFY25 $24.0M

Operating Income

+5.8% YoY

$98.5MFY 2025

FY22 $250.3MFY23 $-945.4MFY24 $93.1MFY25 $98.5M

EPS (Diluted)

+1400.0% YoY

$0.15FY 2025

FY22 $0.96FY23 $-6.45FY24 $0.01FY25 $0.15

Total Assets

+13.1% YoY

$396.9MFY 2025

FY22 $1.10BFY23 $471.1MFY24 $350.9MFY25 $396.9M

Total Debt

—FY 2025

FY22 $396.3MFY23 $397.9MFY24 $199.0MFY25 —

Op. Cash Flow

+22.7% YoY

$127.0MFY 2025

FY22 $273.8MFY23 $183.4MFY24 $103.5MFY25 $127.0M

Free Cash Flow

+22.8% YoY

$127.0MFY 2025

FY22 $273.6MFY23 $183.2MFY24 $103.4MFY25 $127.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$296.2M -15.7%	$351.4M -20.6%	$442.7M +7.8%	$410.6M -0.8%	$413.8M +6.2%	$389.5M
Net Income	$24.0M +2629.2%	$880.0K +100.1%	$-1.00B -672.5%	$175.1M -66.9%	$528.4M +397.7%	$106.2M
Operating Income	$98.5M +5.8%	$93.1M +109.8%	$-945.4M -477.7%	$250.3M +7.8%	$232.3M +62.5%	$142.9M
EPS (Diluted)	$0.15 +1400.0%	$0.01 +100.2%	$-6.45 -771.9%	$0.96 -70.1%	$3.21 +386.4%	$0.66
Total Assets	$396.9M +13.1%	$350.9M -25.5%	$471.1M -57.2%	$1.10B -2.3%	$1.13B +101.5%	$559.2M
Total Debt	—	$199.0M -50.0%	$397.9M +0.4%	$396.3M -12.8%	$454.2M +5.6%	$430.3M
Operating Cash Flow	$127.0M +22.7%	$103.5M -43.5%	$183.4M -33.0%	$273.8M +4.5%	$261.9M +55.1%	$168.8M
Free Cash Flow	$127.0M +22.8%	$103.4M -43.5%	$183.2M -33.1%	$273.6M +4.6%	$261.6M +56.7%	$167.0M

Get alerted when IRWD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IRONWOOD PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IRWD

BlackRock, Inc.
$74.9M17,788,557 sh
ARMISTICE CAPITAL, LLC
$58.7M13,932,000 sh
Sarissa Capital Management LP
$38.7M9,188,635 sh
STATE STREET CORP
$37.1M8,809,601 sh
BANK OF AMERICA CORP /DE/
$36.6M8,683,803 sh
RENAISSANCE TECHNOLOGIES LLC
$33.7M7,993,226 sh
VANGUARD CAPITAL MANAGEMENT LLC
$27.8M6,608,508 sh
AQR CAPITAL MANAGEMENT LLC
$27.2M6,465,921 sh
ACADIAN ASSET MANAGEMENT LLC
$24.6M5,853,331 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$23.2M5,513,355 sh

Fund	Value	Shares
BlackRock, Inc.	$74.9M	17,788,557
ARMISTICE CAPITAL, LLC	$58.7M	13,932,000
Sarissa Capital Management LP	$38.7M	9,188,635
STATE STREET CORP	$37.1M	8,809,601
BANK OF AMERICA CORP /DE/	$36.6M	8,683,803
RENAISSANCE TECHNOLOGIES LLC	$33.7M	7,993,226
VANGUARD CAPITAL MANAGEMENT LLC	$27.8M	6,608,508
AQR CAPITAL MANAGEMENT LLC	$27.2M	6,465,921
ACADIAN ASSET MANAGEMENT LLC	$24.6M	5,853,331
VANGUARD PORTFOLIO MANAGEMENT LLC	$23.2M	5,513,355

Companies Similar to IRWD

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INVA

Innoviva, Inc.

AI score

Similar quality profile · 11 shared holders

Sarissa Capital Management LP LSV ASSET MANAGEMENT SEGALL BRYANT & HAMILL, LLC

RIGL

RIGEL PHARMACEUTICALS INC

AI score

Similar quality profile · 11 shared holders

ARMISTICE CAPITAL, LLC SEGALL BRYANT & HAMILL, LLC CM Management, LLC

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 17 shared holders

ARMISTICE CAPITAL, LLC JACOBS LEVY EQUITY MANAGEMENT, INC WEDGE CAPITAL MANAGEMENT L L P/NC

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 9 shared holders

SEGALL BRYANT & HAMILL, LLC GLOBEFLEX CAPITAL L P MARTINGALE ASSET MANAGEMENT L P

INSP

Inspire Medical Systems, Inc.

AI score

Similar quality profile · 5 shared holders

MARTINGALE ASSET MANAGEMENT L P LSV ASSET MANAGEMENT AXQ CAPITAL, LP

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 11 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC SEGALL BRYANT & HAMILL, LLC Virtus Investment Advisers, LLC

EXEL

EXELIXIS, INC.

AI score

Similar quality profile · 10 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Hillsdale Investment Management Inc.Robeco Institutional Asset Management B.V.

JAZZ

Jazz Pharmaceuticals plc

AI score

Similar quality profile · 9 shared holders

WEDGE CAPITAL MANAGEMENT L L P/NC Robeco Institutional Asset Management B.V.LSV ASSET MANAGEMENT

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IRWD on your watchlist

Track score changes the day IRONWOOD PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IRWD a good stock to buy?

13F Pro's AI-powered analysis of IRONWOOD PHARMACEUTICALS INC (IRWD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IRWD are available on the IRWD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IRWD is classified as a small company.

Which hedge funds own IRWD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IRWD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IRONWOOD PHARMACEUTICALS INC's investment landscape.